Skip to main content
Premium Trial:

Request an Annual Quote

University of Texas to Use IBM Grid Tech for Genomics, Proteomics Research

NEW YORK, March 18 (GenomeWeb News) - The University of Texas at Austinwill use IBM's grid technology to help it perform genomics and proteomics research, according to a local media report yesterday.


Leading the project, called UT Grid, will be the TexasAdvancedComputingCenterat Austin, UT's Information Technology Services department, the Institute for Computational and Engineering Sciences, the Center for Instructional Technologies, and the Collegeof Engineering, according to IT Utility Pipeline News.

The UT Grid will be based on TACC's GridPort3 grid portal toolkit, and will enable students and faculty to use all UT Grid systems, the report said. GridPort3 will also be used to construct specialized science portals, and IBM and TACC plan to co-develop grid application software using the Web Services-Resources Framework and Web Services-Notification specifications, according to the report.

Lastly, the university intends to link the Grid to "other major grid projects" such as the National Science Foundation's TeraGrid.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.